Real-time Three-dimensional Echocardiographic Assessment of Left Ventricular Remodeling Index in Patients with Hypertensive Heart Disease and Coronary Artery Disease

Left ventricular remodeling index （LVRI） was assessed in patients with hypertensive heart disease （HHD） and coronary artery disease （CAD） by real-time three-dimensional echocardiography （RT3DE）. RT3DE data of 18 patients with HHD, 20 patients with CAD and 22 normal controis （NC） were acquired. Left ventricular end-diastolic volume （EDV） and left ventricular end-diastolic epicardial volume （EDVepi） were detected by RT3DE and two-dimensional echocardiography Simpson biplane method （2DE）. LVRI （left ventricular mass/EDV） was calculated and compared. The results showed that LVRI measurements detected by RT3DE and 2DE showed significant differences inter-groups （P〈0.01）. There was no significant difference in NC group （P〉0.05）, but significant difference in HHD and CAD intra-group （P〈0.05）. There was good positive correlations between LVRI detected by RT3DE and 2DE in NC and HHD groups （t=0.69, P〈0.01; r=0.68, P〈0.01）, but no significant correlation in CAD group （r=0.30, P〉0.05）. It was concluded that LVRI derived from RT3DE as a new index for evaluating left ventricular remodeling can provide more superiority to LVRI derived from 2DE.

Clinical Efficacy of Ningxin Tongluo Decoction(宁心通络汤)Combined with Dapagliflozin on Patients of Type 2 Diabetes Mellitus Complicated with Ventricular Premature Beats

Objective:To explore the clinical efficacy of Ningxin Tongluo Decoction(宁心通络汤)combined with Dapagliflozin in the treatment of type 2 diabetes mellitus complicated with ventricular premature beats.Methods:Ninety-two patients with type 2 diabetes mellitus complicated with ventricular premature beats in our hospital were randomly divided into control group(n=46)and observation group(n=46).The control group was treated with routine Western medicine,and the observation group was treated with Ningxin Tongluo Decoction on the basis of the control group.The clinical efficacy of the two groups before and after treatment,TCM syndrome score,blood glucose levels[fasting blood glucose(GLU),glycosylated hemoglobin(Hb A1c)],glucose metabolism levels[fasting insulin(FINS),insulin resistance index(HOMA-IR)],the number of ventricular premature beats detected by 24-hour ambulatory electrocardiogram,heart rate turbulence(HRT)[initial oscillation(TO),oscillation slope(TS)],and heart rate variability(HRV)standard deviation of two normal R-R intervals(SDNN),standard deviation of average normal R-R intervals every 5 minutes(SDANN)and root mean square of adjacent normal R-R intervals(RMSSD)were observed.Results:After treatment,the total effective rate of the observation group was 89.13%,significantly higher than that of the control group(73.91%),and the difference was statistically significant(P<0.05).Both groups could reduce TCM syndrome score,blood glucose level,glucose metabolism level,reduce the number of ventricular premature beats,improve HRT and HRV levels,and the observation group was superior to the control group,and the difference was statistically significant(P<0.05).Conclusion:Ningxin Tongluo Decoction combined with Dapagliflozin is effective in treating type 2 diabetes mellitus patients with ventricular premature beats.It can reduce blood glucose level,improve HRV and HRT,improve autonomic nerve function and exert antiarrhythmic effect.

Effects of telmisartan combined with nifedipine controlled release tablet on inflammatory factors, vascular endothelial function and left ventricular function in patients with coronary heart disease with mild to moderate hypertension

Objective: To investigate the effect of telmisartan combined with Nifedipine Controlled Release Tablet on inflammatory factors, vascular endothelial function and left ventricular function in patients with coronary heart disease with mild to moderate hypertension. Methods:A total of 92 cases of patients with coronary heart disease with mild to moderate hypertension were selected as the object of observation, according to the random data table, they were divided into the control group (n=46) and observation group (n=46), and patients in the control group were treated with Nifedipine Controlled Release Table therapy, on this basis, the observation group patients were given telmisartan treatment, two groups were treated for 6 months. The levels of the blood pressure, inflammatory factors, vascular endothelial function and left ventricular function compared between the two groups before and after treatment. Results: There were no significant differences in the levels of SBP, DBP, hs-CRP, TNF-α, NO, ET-1, LVEF, LVEDD and LVESD in the two groups before treatment. After treatment, two groups of SBP, DBP, hs-CRP, TNF-α, ET-1, LVEDD and LVESD levels were significantly lower than those in the same group before treatment, and after treatment, the levels of SBP, DBP, hs-CRP, TNF-α, ET-1 and LVESD in the observation group were significantly lower than those in the control group, while there were no significant difference in the level of LVEDD between the two groups after treatment;Compared with level in the group before treatment, the levels of NO and LVEF in the two groups were significantly increased, and the observation group [(82.13±19.01) μmol/L, (52.83±7.45)%] was significantly higher than the control group ((67.37±13.08) μmol/L, (49.47±6.96)%)Conclusion: Telmisartan combined with Nifedipine Controlled Release Table in treating coronary heart disease with mild to moderate hypertension, can effectively control blood pressure, reduce the inflammatory stress, improve vascular endothelial function and left ventricular function of patients, has an important clinical value.

Pulmonary Arterial Hypertension Medical Management of the Adult Patient with Congenital Heart Disease

Congenital heart disease(CHD)-associated pulmonary arterial hypertension(PAH)includes a heterogeneous patient population that can be characterized by the underlying cardiac malformation.CHD-associated PAH has an estimated prevalence of 5– 10% in adult patients,with an increasing number of patients surviving to adulthood because of advances in the surgical management and the development of pulmonary arterial hypertension(PAH)-targeted pharmacotherapy.Although limited data exist,targeted PAH pharmacotherapy has proven to be benefi cial in patients with CHD-associated PAH,with observed improvement in functional class,increase in exercise capacity,and improvement in quality of life and cardiopulmonary hemodynamics.Additionally,there has been increasing interest in the“treat-to-close”strategy.PAH-targeted pharmacotherapy may be used to optimize cardiopulmonary hemodynamics so as to improve patients’operability in repairing the cardiac defect.Although there have been signifi cant advances in the management of this disease state in the past 2 decades,mortality remains high,and ongoing clinical trials are needed to better understand the treat-to-close strategy.

Animal models of pulmonary hypertension due to left heart disease

Pulmonary hypertension due to left heart disease(PH-LHD) is regarded as the most prevalent form of pulmonary hypertension(PH). Indeed, PH is an independent risk factor and predicts adverse prognosis for patients with left heart disease(LHD). Clinically, there are no drugs or treatments that directly address PH-LHD, and treatment of LHD alone will not also ameliorate PH. To target the underlying physiopathological alterations of PH-LHD and to develop novel therapeutic approaches for this population, animal models that simulate the pathophysiology of PH-LHD are required. There are several available models for PH-LHD that have been successfully employed in rodents or large animals by artificially provoking an elevated pressure load on the left heart, which by transduction elicits an escalated pressure in pulmonary artery. In addition, metabolic derangement combined with aortic banding or vascular endothelial growth factor receptor antagonist is also currently applied to reproduce the phenotype of PH-LHD. As of today, none of the animal models exactly recapitulates the condition of patients with PH-LHD. Nevertheless, the selection of an appropriate animal model is essential in basic and translational studies of PH-LHD. Therefore, this review will summarize the characteristics of each PH-LHD animal model and discuss the advantages and limitations of the different models.

THE EXPESSION OF ENDOTHELIN-1 IN VENTRICULAR SPETAL DEFECT WITH PULMONARY HYPERTENSION

Objective To research the expression of endothelin-1 (ET-1) in vascular of lung, endocardium and myocardial vascular of congenital heart disease (CHD) ventricular septal defect (VSD) with pulmonary hypertension (PH). Methods The Streptavidin-peroxidase (SP) immunoassay was used to measure the expression of ET-1 in pulmonary arteriola, pulmonary veinlet, endocardium and endangium of vasa coronary of 20 cases VSD of CHD with PH, and contrast the expression level of these 20 cases VSD of CHD with PH. Results The expression of ET-1 PH patients in pulmonary arteriola, endocardium, and endangium of vasa coronary was much higher than that of the control group (P<0.05), but there was no significance variance in expression level of pulmonary veinlet between two groups (P>0.05). Conclusion If VSD of CHD was accompany with PH, the degree of PH has a positive correlation with the amount of ET-1 in pulmonary arteriola, ET-1 may be the cause of dynamic PH, and also the acceleration factor of the PH. However, the amount of ET-1 in endocardium and endangium of vasa coronary, may have significant connection with the myocardium hypertrophy in dynamic PH.

不同年龄段早发冠心病患者临床特征及危险因素的分析

目的:探究不同年龄段早发冠心病患者的临床特征以及危险因素。方法:选择2021年6月至2022年8月,在北京安贞医院门诊诊断为早发冠心病的380例患者作为研究对象,40岁<患者年龄≤59岁为中青年组,中青年组150例,59岁<患者年龄≤65岁为老年组,老年组230例。对两组患者的临床资料、实验室检查指标、冠心病的影响因素、冠状动脉病变情况及介入治疗后安全性,进行单因素分析,对单因素分析差异有统计学意义的因素带入多元线性回归,分析相关影响因素。结果:两组患者一般资料对比,仅性别差异有统计学意义(P<0.05)。与中青年组相比,老年组患者的Cr、血浆凝血酶原时间(prothrombin time,PT)、FIB水平明显高,但老年组的谷氨酸转肽酶、TG、Hcy以及PLT都明显低于中青年组,差异有统计学意义(P<0.05)。多因素Logistic回归分析结果显示,Hcy、FIB进入回归模型;老年组3支病变者发生率均比较高(P<0.05),冠状动脉造影术后总的不良事件发生率更多(P<0.05)。结论:不同年龄段早发冠心病患者在临床实验室指标及预后方面存在差异。

参松养心胶囊治疗老年冠心病室性早搏气阴两虚、心络瘀阻型患者临床观察

目的:观察参松养心胶囊对老年冠心病室性早搏气阴两虚、心络瘀阻型患者临床疗效、动态心电图室性早搏次数及中医证候积分的影响。方法:选择老年冠心病室性早搏气阴两虚、心络瘀阻型患者60例,按照随机数字表法分为对照组和观察组,每组30例。对照组给予口服酒石酸美托洛尔,观察组在对照组基础上口服参松养心胶囊。两组均连续治疗4周。观察两组治疗前后临床疗效,24 h动态心电图室性早搏次数及中医证候积分。结果:对照组有效率[73.33%(22/30)]高于观察组[96.67%(29/30)](P<0.05)。两组治疗后室性早搏次数均减少,观察组减少较对照组更明显(P<0.05)。与治疗前比较,两组心悸、悸动不安、神疲乏力、气短、五心烦热等中医证候积分均下降(P<0.05),且治疗后观察组上述指标改善优于对照组(P<0.05)。结论:参松养心胶囊能有效减少老年冠心病室性早搏患者的室性早搏次数,改善患者临床症状。

升陷汤加味联合酒石酸美托洛尔治疗气虚下陷型室性早搏患者的疗效及其对心电图指标及心率震荡的影响

目的探讨升陷汤加味联合酒石酸美托洛尔治疗气虚下陷型室性早搏患者的疗效及其对心电图指标和心率震荡的影响。方法选择2019年8月至2023年1月中国中医科学院广安门医院接收的160例气虚下陷型室性早搏患者为研究对象进行前瞻性研究,根据随机数字表法将其分为中西组和对照组,每组各80例。对照组采用酒石酸美托洛尔治疗,中西组采用酒石酸美托洛尔+升陷汤加味治疗,均连续用药8周。比较两组总有效率,治疗前、治疗8周后的中医证候积分、室性早搏发作次数、心电图指标、心率震荡参数及不良反应情况。结果治疗8周后,中西组总有效率为93.75%,明显高于对照组(80.00%),差异有统计学意义(P<0.05)。治疗8周后,两组证候积分、室性早搏发作次数均较治疗前显著下降,且中西组的证候积分、室性早搏发作次数分别为(6.61±0.83)分、(112.61±13.83)次/h,显著低于对照组[(10.05±1.32)分、(151.05±17.32)次/h],差异均有统计学意义(P<0.05)。治疗8周后,两组PR间期均较治疗前显著缩短,QRS波时限、QTc间期均较治疗前显著延长,且中西组的PR间期为(0.132±0.014)ms,显著短于对照组[(0.141±0.016)ms],QRS波时限、QTc间期分别为(0.093±0.013)、(0.496±0.052)s,均显著长于对照组[(0.082±0.011)、(0.433±0.047)s],差异均有统计学意义(P<0.05)。治疗8周后,两组T0水平均较治疗前显著下降,TS水平均较治疗前显著上升,且中西组的T0水平为(0.09±0.02)%,显著低于对照组[(0.21±0.05)%],TS水平为(5.72±0.83)ms/RR,显著高于对照组[(4.45±0.66)ms/RR],差异均有统计学意义(P<0.05)。中西组与对照组的总不良反应发生率比较,差异无统计学意义(P>0.05)。结论采用升陷汤加味联合酒石酸美托洛尔治疗气虚下陷型室性早搏患者可有效减少患者早搏次数,调节心功能,效果较为理想,临床应用价值较高。

温阳复脉益心加减方联合铜砭刮痧治疗老年冠心病并发心律失常疗效研究

目的:探究温阳复脉益心加减方联合铜砭刮痧治疗老年冠心病并发心律失常的临床价值。方法:选取冠心病并发心律失常患者94例,依据简单随机数字表法分为中西医组、西医组,各47例。西医组口服胺碘酮、美托洛尔,中西医组在西医组基础上采取温阳复脉益心加减方联合铜砭刮痧,两组均治疗1个月。统计两组治疗前后中医证候积分、临床疗效、心率、短阵室性心动过速数量、室性早搏数量、校正QT间期(QTc)、QT离散度(QTd)、不良反应发生情况。结果:治疗后两组胸闷气短、心悸不安、眩晕、自汗懒言、神疲乏力、形寒肢冷、面色白评分较治疗前下降,且中西医组低于西医组,差异有统计学意义(均P<0.05)。中西医组治疗总有效率93.62%高于西医组78.72%,差异有统计学意义(均P<0.05)。治疗后两组静息心率、24 h最快心率、24 h最慢心率、24 h平均心率、24 h总心率较治疗前增高,且中西医组高于西医组,差异有统计学意义(均P<0.05)。治疗后两组短阵室性心动过速数量、室性早搏数量少于治疗前,且中西医组少于西医组,差异有统计学意义(均P<0.05)。治疗后两组QTc、QTd较治疗前降低,且中西医组低于西医组,差异有统计学意义(均P<0.05)。中西医组不良反应发生率6.38%与西医组10.64%比较,差异无统计学意义(P>0.05)。结论:温阳复脉益心加减方联合铜砭刮痧治疗老年冠心病并发心律失常可改善心率,缓解临床症状,提升治疗效果,且较安全。

频发室性早搏与心脏瓣膜手术同期迷宫手术后心房颤动复发关系研究

目的:探讨频发室性早搏(VPB)与心脏瓣膜手术同期射频消融迷宫手术(CMA)后心房颤动(AF)复发的关系。方法:收集因瓣膜疾病合并AF行心脏瓣膜手术同期射频消融迷宫手术的患者115例进行单中心、回顾性、病例对照研究,按照AF是否复发进行分组,复发AF患者23例,未复发患者92例。收集患者一般临床资料和相关实验室检查并评估术前室性早搏负荷(室性早搏数量>10000个/24 h为频发室性早搏)。采用单因素和多因素Cox比例风险回归模型对合并瓣膜疾病的AF患者在接受心脏瓣膜手术及同期射频消融迷宫手术后AF复发的危险因素进行分析。结果:与未复发组比较,复发组室性早搏负荷较高(P<0.05)。多因素Cox回归分析结果显示,频发室性早搏和糖尿病是进行心脏瓣膜手术并同期接受射频消融迷宫手术的患者AF复发的独立危险因素(均P<0.05)。结论:频发室性早搏是心脏瓣膜手术同期射频消融迷宫手术后心房颤动复发的危险因素。

稳心颗粒联合胺碘酮治疗心力衰竭并发室性心律失常有效性及安全性的Meta分析

目的:系统评价稳心颗粒结合胺碘酮治疗心力衰竭并发室性心律失常的疗效与安全性。方法:计算机检索中国知网(CNKI)、维普网(VIP)、万方、中国生物医学文献数据库(CBM)、PubMed、Web of Science和the Cochrane Library等数据库,检索有关稳心颗粒联合胺碘酮治疗心力衰竭并发室性心律失常的随机对照试验(RCT)。由2名研究者分别对文献进行筛选、提取数据和评价纳入研究的偏倚风险后,采取RevMan 5.3及R语言统计软件进行Meta分析。结果:共纳入18项研究,涉及1 527例病人。Meta分析结果显示,稳心颗粒联合胺碘酮治疗心力衰竭并发室性心律失常,在提高临床总有效率[RR=1.19,95%CI(1.14,1.25),P<0.000 1]、减少室性期前收缩次数[SMD=-2.42,95%CI(-4.66,-0.18),P=0.03]、稳定心率[SMD=-1.66,95%CI(-1.94,-1.37),P<0.000 1]、增加左室射血分数[SMD=1.57,95%CI(0.54,2.61),P=0.003]均优于单独使用胺碘酮,且不良反应发生率低于单独使用胺碘酮[RR=0.59,95%CI(0.43,0.80),P=0.000 8]。结论:现有证据表明,稳心颗粒联合胺碘酮在治疗心力衰竭并发室性心律失常,能够明显提高临床疗效、LVEF,且不良反应更少,安全性较好。

心脏磁共振评估结缔组织病伴重度肺动脉高压的价值

目的评估心脏磁共振(CMR)对重度结缔组织病相关肺动脉高压(CTD-PAH)患者的诊断价值。方法纳入经右心导管(RHC)检查确诊为CTD-PAH的患者。在CMR图像上手动勾画并经体表面积校正获得右心室(RV)形态、功能及室间隔(IVS)的相关参数;在心肌延迟强化(LGE)图像上手动勾画并计算得到LGE心肌质量(MM)及其占左心室(LV)MM百分比。依照平均肺动脉压(mPAP)将其分为轻中度组和重度组,比较2组患者CMR参数差异,采用受试者工作特征(ROC)曲线分析CMR对重度患者的诊断价值。结果本研究共纳入48例CTD-PAH患者。重度组患者室间隔曲率(CIVS)及RV射血分数(EF)低于轻中度组,IVS形变时间占比、RV舒张末期容积指数(EDVI)、RV收缩末期容积指数(ESVI)及RV MM高于轻中度组(均P<0.05)。ROC曲线分析显示RV MM、IVS形变时间占比及RV ESVI对重度患者具有较好的诊断效能(AUC分别为0.792、0.766、0.731)。联合检测曲线下面积为0.840,敏感度为79.4%,特异度为85.7%。结论CMR测得的RV及IVS参数能够有效地评估重度CTD-PAH患者,从形态和功能学的角度直接反映了重度CTD-PAH患者的心脏受损程度。

CMR在高血压心脏病中的应用进展

高血压作为各种心血管疾病的最重要诱因,会引起心脏结构变化、冠脉微循环障碍等一系列适应性改变,因此,对高血压患者心脏结构和功能的评价显得格外重要。临床上常用于评价心脏结构和功能的工具为超声心动图,但心脏磁共振(cardiac magnetic resonance,CMR)较其具有更好的软组织分辨率及多功能、多参数成像的优点,可通过电影序列、T2WI、灌注成像序列、早期强化序列以及延迟强化序列(late gadolinium enhancement,LGE)、增强前后T1 mapping对高血压心脏病(hypertensiveheartdisease,HHD)进行全方位评估。本文通过总结这些技术对高血压引起的左室肥厚(leftventricular hypertrophy,LVH)、心肌纤维化、收缩舒张功能降低、冠脉微循环障碍等方面进行的定量、定性分析,对指导临床决策、改善患者预后有重要意义,并有望为将来的研究提供参考方向。

血清proBNP和Hcy在冠心病合并高血压中的研究进展

高血压是临床上极为常见的一种心血管疾病,且该类患者往往合并了冠心病,这直接导致了心血管事件的发生风险倍增。目前大量研究表明血清脑钠肽前体(proBNP)、同型半胱氨酸(Hcy)与冠心病合并高血压患者左心室几何构型和功能的异常密切相关。本文就血清proBNP和Hcy的概念、在冠心病和高血压诊断中的临床应用、与冠心病和高血压的关系、引起左心室几何构型及功能异常的机制、指导冠心病合并高血压的治疗进行综述,为预防左心室异常提供参考依据。

桂枝甘草汤加味治疗室性早搏心肾阳虚证患者的临床疗效分析

目的评估桂枝甘草汤加味治疗室性早搏心肾阳虚证患者的效果。方法58例室性早搏心肾阳虚证患者,随机分为观察组和对照组,各29例。对照组给予胺碘酮治疗,观察组在对照组基础上给予自拟桂枝甘草汤加味治疗。比较两组临床疗效及治疗后心率变异性(HRV)指标[全部窦性R-R间期的标准差(SDNN)、每5分钟窦性R-R间期均值的标准差(SDANN)、每5分钟窦性R-R间期标准差平均值(SDNNI)、正常相邻R-R间期差值>50 ms的百分比(PNN50)]、心功能指标[左室射血分数(LVEF)、左心室短轴缩短率(LVFS)、每搏输出量(SV)及B型脑钠肽(BNP)]、生活质量评分。结果治疗后,观察组总有效率89.7%显著高于对照组的65.5%,差异有统计学意义(P<0.05)。治疗后,观察组SDNN(118.92±13.72)ms、SDANN(114.82±12.96)ms、SDNNI(47.02±5.86)ms、PNN50(9.33±0.94)%、SV(79.92±8.87)ml、LVFS(25.07±2.76)%、LVEF(50.02±5.96)%及BNP(239.281±20.93)ng/L均显著优于对照组的(103.53±11.64)ms、(101.63±10.14)ms、(39.93±4.96)ms、(6.11±0.72)%、(73.33±8.42)ml、(21.83±2.34)%、(45.23±5.74)%、(386.71±36.71)ng/L,差异有统计学意义(P<0.05)。治疗后,观察组身体健康、心理状态、社会功能、日常生活能力评分均显著优于对照组,差异有统计学意义(P<0.05)。结论通过桂枝甘草汤加味治疗室性早搏心肾阳虚证患者,可以显著降低心率变异性,改善患者心功能,提高患者生活质量,疗效确切,可以在临床推广使用。

胺碘酮联合美托洛尔治疗慢性心力衰竭合并室性早搏患者的效果

目的:观察胺碘酮联合美托洛尔治疗慢性心力衰竭(CHF)合并室性早搏患者的效果。方法:回顾性分析2022年4月至2023年4月该院收治的92例CHF合并室性早搏患者的临床资料,根据治疗方法不同将其分为对照组和研究组各46例。对照组采用美托洛尔治疗,研究组在对照组基础上联合胺碘酮治疗。比较两组治疗效果、治疗前后心率变异性指标[全部窦性心搏RR间期标准差(SDNN)、相邻RR间期差值的均方根(RMSSD)、正常RR间期的标准差(SDANN)]水平、早搏发作频率、心功能指标[左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)、左心室射血分数(LVEF)]水平、血管内皮功能指标[一氧化氮(NO)、内皮素-1(ET-1)、降钙素基因相关肽(CGRP)、肱动脉内皮依赖性血管舒张功能(FMD)]水平,以及不良反应发生率。结果:研究组治疗总有效率为93.48%(43/46),高于对照组的65.22%(30/46),差异有统计学意义(P<0.05);治疗后,两组SDNN、RMSSD、SDANN水平均高于治疗前,且研究组高于对照组,两组早搏发作频率均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);治疗后,两组LVEDD、LVESD水平均低于治疗前,且研究组低于对照组,两组LVEF水平均高于治疗前,且研究组高于对照组,差异有统计学意义(P<0.05);治疗后,两组FMD、NO、CGRP水平均高于治疗前,且研究组高于对照组,两组ET-1水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:胺碘酮联合美托洛尔治疗CHF合并室性早搏患者可提高治疗总有效率和心率变异性指标水平,改善心功能指标、血管内皮功能指标水平,降低早搏发作频率,其效果优于单纯美托洛尔治疗。

动态心电图对老年冠状动脉性心脏病患者心肌缺血及心律失常的诊断效果

目的探究存在心律失常、心肌缺血问题的老年冠状动脉性心脏病经过动态心电图检查后的诊断效果。方法选取我院收治的86例老年冠状动脉性心脏病患者,时间段为2022年1月至2024年2月,随机分成两组,对照组、观察组各43例,分别接受常规心电图、动态心电图诊断。结果观察组的心房颤动、房性早搏、室性早搏、房室传导阻滞以及心肌缺血检出率更高(P<0.05);观察组的临床诊断满意度高于对照组(P<0.05)。结论在临床治疗过程中,运用动态心电图方法可以在短时间内准确检测出所存在的心律失常、心肌缺血问题,进而提高临床诊断满意度。

美托洛尔联合胺碘酮对冠心病合并室性早搏的疗效及心率变异性的影响

目的 分析美托洛尔联合胺碘酮治疗冠心病合并室性早搏的效果。方法 选取198例冠心病合并室性早搏患者,按随机数字表法分为对照组和观察组两组,每组各99例。对照组口服胺碘酮治疗,观察组采用胺碘酮加美托洛尔口服治疗,两组疗程均为1个月。对比两组临床疗效、动态心电图参数、心率变异性(heart rate variability, HRV)指标、心功能指标及不良反应的发生情况。结果 观察组治疗总有效率明显高于对照组,且治疗后的QT间期离散度、校正的QT间期离散度均明显低于对照组,各项HRV指标、心功能指标均优于对照组(均P<0.05);两组治疗期间均未出现不良反应。结论 在使用胺碘酮的基础上加用美托洛尔治疗冠心病合并室性早搏,可进一步改善患者的HRV指标和心功能,显著提高疗效,值得在临床推广。

稳心颗粒联合常规西药治疗慢性肺源性心脏病合并频发室性期前收缩的临床效果

目的:探讨稳心颗粒联合常规西药治疗慢性肺源性心脏病合并频发室性期前收缩的临床效果。方法:选取2019年3月—2022年3月济南市莱芜区高庄街道社区卫生服务中心收治的慢性肺源性心脏病合并频发室性期前收缩患者88例作为研究对象,随机分为试验组和对照组,各44例。试验组采用常规西药和稳心颗粒治疗,对照组给予常规西药治疗。比较两组治疗效果。结果:试验组治疗总有效率高于对照组,差异有统计学意义(P=0.013)。治疗后,两组第1秒用力呼气容积(FEV1)、用力肺活量(FVC)、FEV1/FVC均高于治疗前,且试验组高于对照组,差异有统计学意义(P<0.05)。治疗后,两组社会关系、心理方面、生活功能、精神状态评分均高于治疗前,且试验组高于对照组,差异有统计学意义(P<0.05)。治疗后,两组室性期前收缩次数均少于治疗前,且试验组少于对照组,差异有统计学意义(P<0.05)。结论:稳心颗粒联合常规西药治疗慢性肺源性心脏病合并频发室性期前收缩的临床效果显著,可改善患者肺功能及生活质量,减少室性期前收缩次数。